Work

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-198740

Authors: Debashree Basudhar, Dante Descalzi-Montoya, Hao Tang, Minshi Wang, Fan Wu, P. Leif Bergsagel, Xavier Leleu, Daniela Hosseyni, Maria Chaudhry, Nathan Martin, Ethan G. Thompson

Institutions: Bristol-Myers Squibb (United States), Mayo Clinic Hospital

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405040035

Cites:

Cited by: 2

Related to: 10